Surveillance for Plasmodium falciparum drug resistance mutations is becoming an established tool for assessing antimalarial treatment effectiveness. We used an extended version of a high-throughput post-PCR multiplexed ligase detection reaction fluorescent microsphere assay (LDR-FMA) to detect single-nucleotide P. falciparum drug resistance polymorphisms in 402 isolates from children in Papua New Guinea (PNG) participating in an antimalarial treatment trial. There was a fixation of P. falciparum crt (pfcrt) K76T, pfdhfr C59R and S108N, and pfmdr1 mutations (92%, 93%, 95%, and 91%, respectively). Multiple mutations were frequent. Eighty-eight percent of isolates possessed a quintuple mutation (underlined), SVMNT, NRNI, KAA, and YYSND, in codons 72 to 76 for pfcrt; 51, 59, 108, and 164 for pfdhfr; 540, 581, and 613 for pfdhps; and 86, 184, 1034, 1042, and 1246 for pfmdr1, and four of these carried the K540E pfdhps allele. The pfmdr1 D1246Y mutation was associated with PCR-corrected day 42 in vivo treatment failure in children allocated piperaquinedihydroartemisinin (P ؍ 0.004). Although the pfmdr1 NFSDD haplotype was found in only four isolates, it has been associated with artemether-lumefantrine treatment failure in Africa. LDR-FMA allows the large-scale assessment of resistance-associated single-nucleotide polymorphisms (SNPs). Our findings reflect previous heavy 4-aminoquinoline/sulfadoxine-pyrimethamine use in PNG. Since artemether-lumefantrine and piperaquine-dihydroartemisinin will become first-and second-line treatments, respectively, the monitoring of pfmdr1 SNPs appears to be a high priority.Resistance of Plasmodium species to 4-aminoquinoline drugs emerged in Papua New Guinea (PNG) in 1976 and then spread across the country (18, 24). In addition, mass pyrimethamine dosing in the 1960s led to high-level resistance, and in vitro (38) and in vivo (11, 21) chloroquine (CQ) or amodiaquine (AQ) monotherapy was retained as the first-line treatment for uncomplicated malaria until 2000, when sulfadoxine-pyrimethamine (SP) was added to improve clinical efficacy (5). Despite initial successes, cure rates have since declined (21, 24).Single-nucleotide polymorphisms (SNPs) in parasite genes determining drug effects can underlie resistance. This includes mutations in the Plasmodium falciparum CQ transporter (pfcrt) gene (3, 15), but higher-level CQ resistance results from other SNPs and is inversely associated with the copy number of the P. falciparum multidrug resistance 1 (pfmdr1) gene (16,35,37). pfmdr1 polymorphisms also confer resistance to other antimalarial drugs, including mefloquine, lumefantrine, and quinine (6,33,37). Of particular concern are the results of a previously reported pfmdr1 gene allelic replacement study in which various polymorphisms reduced artemisinin susceptibility in cloned parasite lines (37). Polymorphic changes in the genes encoding dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps) underlie parasite resistance to pyrimethamine (7, 34) and sulfadoxine (44, 45), respe...